These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Durable complete remission with combination chemotherapy and bortezomib in HIV-associated plasmablastic lymphoma. Arora N; Gupta A; Sadeghi N BMJ Case Rep; 2017 Oct; 2017():. PubMed ID: 28993364 [TBL] [Abstract][Full Text] [Related]
11. Infusional dose-adjusted epoch plus bortezomib for the treatment of plasmablastic lymphoma. Fedele PL; Gregory GP; Gilbertson M; Shortt J; Kumar B; Opat S; Grigoriadis G Ann Hematol; 2016 Mar; 95(4):667-8. PubMed ID: 26801792 [No Abstract] [Full Text] [Related]
12. Successful treatment of refractory retroperitoneal Epstein-Barr virus-positive diffuse large B-cell lymphoma with secondary hemophagocytic syndrome by sequential combination regimen of PD-1 blockade and chimeric antigen receptor T cells: a case report. Yu M; Zhang Q; Xu S; Yin T; Li F Anticancer Drugs; 2022 Jan; 33(1):e769-e775. PubMed ID: 34387604 [TBL] [Abstract][Full Text] [Related]
13. The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma. Dunleavy K; Little RF; Pittaluga S; Grant N; Wayne AS; Carrasquillo JA; Steinberg SM; Yarchoan R; Jaffe ES; Wilson WH Blood; 2010 Apr; 115(15):3017-24. PubMed ID: 20130244 [TBL] [Abstract][Full Text] [Related]
14. Hitting back at lymphoma: How do modern diagnostics identify high-risk diffuse large B-cell lymphoma subsets and alter treatment? Abramson JS Cancer; 2019 Sep; 125(18):3111-3120. PubMed ID: 31287161 [TBL] [Abstract][Full Text] [Related]
15. Plasmablastic lymphoma - single centre experience with infusional EPOCH chemotherapy. Jayachandran PK; Rajan AK; Karunakaran P; Mehra N; Selvarajan G; Kesana S; Dhanushkodi M; Radhakrishnan V; Sagar TG Leuk Res; 2020 Aug; 95():106391. PubMed ID: 32559556 [TBL] [Abstract][Full Text] [Related]
16. Bortezomib plus EPOCH is effective as frontline treatment in patients with plasmablastic lymphoma. Castillo JJ; Guerrero-Garcia T; Baldini F; Tchernonog E; Cartron G; Ninkovic S; Cwynarski K; Dierickx D; Tousseyn T; Lansigan F; Linnik Y; Mogollon R; Navarro JT; Olszewski AJ; Reagan JL; Fedele P; Gilbertson M; Grigoriadis G; Bibas M Br J Haematol; 2019 Feb; 184(4):679-682. PubMed ID: 29527667 [No Abstract] [Full Text] [Related]
17. CD56-positive diffuse large B-cell lymphoma/leukemia with Liu Y; Shen J; Awal Issah M; Liu T; Zhou H; Fu H J Int Med Res; 2020 May; 48(5):300060520918087. PubMed ID: 32363958 [TBL] [Abstract][Full Text] [Related]
18. Rituximab with dose-adjusted EPOCH as first-line treatment in patients with highly aggressive diffuse large B-cell lymphoma and autologous stem cell transplantation in selected patients. Pejša V; Prka Ž; Lucijanić M; Mitrović Z; Piršić M; Jakšić O; Ajduković R; Kušec R Croat Med J; 2017 Feb; 58(1):40-48. PubMed ID: 28252874 [TBL] [Abstract][Full Text] [Related]
19. Doxorubicin-Based Chemotherapy and Radiation Therapy Produces Favorable Outcomes in Limited-Stage Plasmablastic Lymphoma: A Single-Institution Review. Pinnix CC; Shah JJ; Chuang H; Costelloe CM; Medeiros LJ; Wogan CF; Reed V; Smith GL; Milgrom S; Patel K; Huo J; Turturro F; Romaguera J; Fayad L; Oki Y; Fanale MA; Westin J; Nastoupil L; Hagemeister FB; Rodriguez A; Qazilbash M; Shah N; Bashir Q; Ahmed S; Nieto Y; Hosing C; Rohren E; Dabaja B Clin Lymphoma Myeloma Leuk; 2016 Mar; 16(3):122-8. PubMed ID: 26795083 [TBL] [Abstract][Full Text] [Related]
20. Incorporating Bortezomib in the Management of Plasmablastic Lymphoma. Umeanaeto O; Gamboa J; Diaz J; Hakim MN; Corral J; Philipovskiy A; Gaur S Anticancer Res; 2019 Sep; 39(9):5003-5007. PubMed ID: 31519607 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]